A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-11000-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Xiang Qin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics (Hematological Oncology), Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for…. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Leukemia, Myeloid, Acute, Cyclooxygenase 2 Inhibitors, Cyclooxygenase 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is an aggressive cancer with complex issues of drug resistance and a poor prognosis; thus, effective therapeutics is urgently needed for AML. In this study, we designed and synthesized dual cyclooxygenase-2 (COX-2) and histone deacetylase (HDAC) inhibitors, IMC-HA and IMC-OPD, and applied them for the treatment of AML. IMC-HA comprised a COX-2 inhibitor skeleton of indomethacin (IMC) and an HDAC inhibitor moiety of the hydroxamic group and was found to exhibit potent antiproliferative activity against AML cells (THP-1 and U937) and low cytotoxicity toward normal cells. Molecular docking simulations suggested that IMC-HA had a high binding affinity for HDAC and COX-2, with binding energies of -6.8 and -9.0 kcal/mol, respectively. Mechanistic studies revealed that IMC-HA induced apoptosis and G0/G1 phase arrest in AML cells, which were characterized by alterations in the expression of apoptotic and cell cycle-related proteins. Further study demonstrated that IMC-HA also inhibited the MEK/ERK signaling pathway in AML cells. Overall, we believe that IMC-HA could serve as a potent COX-2/HDAC dual inhibitor and improve the treatment of AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics (Hematological Oncology), Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical Universit…
- Department of Radiology, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
- Department of Newborn Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
- Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province, Interdisciplinary Research Academy (IRA), Zhejiang Shuren University, Hangzhou, 310015, China. qiuyumeng@zjsru.edu.cn.
- Department of Radiology, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. yanglu@swmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Qin, X., Wang, X., Yang, C., Wang, F., Fang, T., Gu, D., Guo, Q., Meng, Q., Liu, W., & Yang, L. (2025). A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells. Molecular Diversity. https://doi.org/10.1007/s11030-024-11000-w
Vancouver
Qin X, Wang X, Yang C, Wang F, Fang T, Gu D, et al. A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells. Molecular Diversity. 2025. doi:10.1007/s11030-024-11000-w
BibTeX
@article{Qin2025,
author = {Qin, Xiang and Wang, Xueting and Yang, Chunmei and Wang, Fan and Fang, Tingting and Gu, Didi and Guo, Qulian and Meng, Qiuyu and Liu, Wenjun and Yang, Lu},
title = {A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-11000-w}
}
EUVIMED